Drug Approval | June 24, 2022
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
Brings 25 years of global operations and supply chain experience to Piramal
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
Subscribe To Our Newsletter & Stay Updated
